COVID Shield
Amidst the global battle against the covid-19 pedemic the emergence of effective vaccine has been a beacon of hope. Among this life saving solution is COVIDshield in the world vaccination effort. Developed through collaboration between astrazeneca and the University of Oxford COVIDshield represent a significant milestone in the fight against the novel corona virus. With its innovative approach and promising result COVIDshild has gained wide spread attention and adoptionation across the globe. This vaccine is built upon the foundation of adenovirus vector technology hold the promise of immunizing population against the debilating effort of COVID19.
COVIDshield is based on a viral vector platform utilizing a modified adenovirus as a delivery system for the genetic material of the SARS-CoV-2 virus. Adenovirus are a group of common viruses that typically cause mid respiratory infection such as common cold. In this vaccine harmeless version of the adino virus known as ChAdOx1 (chimpanzee adenovirus Oxford 1) as the vector for delivery genetic material. This protein is a key component of the SARS-Co-2 virus responsible for facilitating viral entry into host cell. To generate an immune response against this virus the genetic material in coding the spike is incorporated with the genome of adeno virus vector used in COVIDshield. The production process of COVIDshield invoice genetically modified adenovirus vector to carry the gene in coding the spike protein. The modified adenovirus vector is then grown in cell culture typically using mammalian cell lines under controlled laboratory condition. After the adenovirus vector has replicated and expressed the spike protein gene it is harvested in purified to remove any remaining cellular component and contaminant. Once purified did no virus vector carrying this pipe protein genius formulated into a vaccine. It is a two dose series with the second those given several week usually 4 to 12 week after the first dose. The two dose regiment is designed to prime the immune system with the initial dose and boost and prolong the immune system with the second dose.
COVIDshield can be stored and transported at standard refrigerated temperature make in it suitable for distribution and administration in wide range of setting. I like some other covid-19 vaccine that require Ultra cold storage this does not require so. This can be administered at various vaccination site including healthcare facilities pharmacy clinic community centre and mobile vaccination unit. Trained healthcare personal including doctor nurses pharmacist and other healthcare worker or responsible for administrain COVIDshild and providing information about the vaccine to recipient’s. Public education campaign conducted to raise awareness about this vaccine addressing vaccine hesistancy and provide accurate information about vaccine safety and administration.
COVIDshield has been associated with rare but serious adverse event including cases of blood clotting disorder such as thrombosis with thrombocytopenia syndrome (TTS). Reports of these rare adverse event led to temporary suspension of COVIDshield vaccination in some countries and raised concern about vaccine safety and rest benefit assetment. Regulatory agencies conducted through reviews of COVIDshield safety and efficiency data in response to report of adverse event. Reports of rare adverse event and temporary suspension of this vaccination contributed to vaccine has its tensy and eroded public confidence in the vaccine. Controversy arose over the doosing interval for COVIDshield with some countries extending the interval between first and second those beyond the originally recommended timesframe. Questions were raised about the optimal dozing Regiment for this vaccine and whether longer dosing interval food affect vaccine efficiency and durability of protection. TTS is a rare but serious adverse even that has been associated with COVIDshield.
COVID19 vaccine developed by astrozenica in collaboration with the University of Oxford. TTS in formation of blood clot combined with low level of platelets typically occurring in unusual side such as the cerebral Venous sinuses (CVST). However it is an extreme rare complication following this vaccine occurring in small number of individual who have received the vaccine. The incident of TTS is estimated to be very low with reported case occurring at the rate of fewer than1 of 100,000 vascinated individuals. Individual who developed TTS following this vaccination makes experience symptom such a severe headache, blured vision, confusion, mummy doctor kahan Jana Tha Ab domininal pain shortness of breath and leg swelling. The symptoms typically occur within few days to few week after vaccination. The exact cause of TTS following this vaccination is not fully understood but it is believed to be involved and immune mediated response figured by the adenovirus vector used in the vaccine. This immune response mailly to the activation of platelets and forming the blood clot in unusual location. Some research also suggest that younger age female and a previous history of from beiosis or auto immune disorder maybe associated with an increase risk of TTS. With TTS associated with COVIDshield vaccination is a cause for concerned it is important to emphasize that overall benefit of vaccination in preventing co which shield out with the risk of rare adverse event.
Despite the challenges COVIDshield plays a crucial role in the global referred to control the COVID-19 pandemic It’s relatively simple storage requirement and why this kept ability makes it important tool in vaccanization campaign worldwide. Overall COVIDshield represent a significant milestone in the fight against covid-19 offering hope for a safer and healthier future for population around the world.